Drug intelligence / Profile preview

insulin ultralente + regular insulin

Development stage
Discontinued
Lead developer
Eli Lilly
Modality
Recombinant Proteins and Enzymes
Administration
Subcutaneous
01

Overview

Insulin ultralente + regular insulin is a combination of two types of human insulins used in the management of diabetes mellitus. Insulin ultralente is an ultra long-acting, zinc-based crystalline suspension that provides basal (background) glycemic control, with an onset of 2–4 hours, a broad peak at 8–16 hours, and duration up to 24 hours. Regular insulin is a short-acting form that begins working within 30 minutes to one hour after injection, peaks at about 2–5 hours, and lasts for up to six hours. The combination regimen aims to mimic physiological insulin secretion by providing both basal and prandial (mealtime) coverage. This approach helps improve glycemic control in patients with type 1 or type 2 diabetes who require both background and mealtime glucose regulation[3][5][9]. Both components act as agonists at the insulin receptor, facilitating cellular uptake of glucose from the bloodstream.

02

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on insulin ultralente + regular insulin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on insulin ultralente + regular insulin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call